Persistence of effect of galcanezumab in patients with episodic or chronic migraine: phase 3, randomized, double-blind, placebo controlled EVOLVE-1, EVOLVE-2 and REGAIN studies

被引：0
|
作者：
Aurora, Sheena K. [1 ]
Zhang, Qi [1 ]
Stauffer, Virginia L. [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
JOURNAL OF HEADACHE AND PAIN | 2018年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
O18
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Efficacy of Galcanezumab in Patients Who Failed to Respond to Preventives Previously: Results from EVOLVE-1, EVOLVE-2 and REGAIN Studies
    Zhang, Q.
    Ruff, D.
    Pearlman, E.
    Govindan, S.
    Aurora, S.
    HEADACHE, 2018, 58 : 165 - 166
  • [32] EFFICACY OF GALCANEZUMAB IN PATIENTS WHO FAILED TO RESPOND TO PREVENTIVES PREVIOUSLY: RESULTS FROM EVOLVE-1, EVOLVE-2 AND REGAIN STUDIES
    Zhang, Q.
    Ruff, D. D.
    Pearlman, E. M.
    Govindan, S.
    Aurora, S.
    CEPHALALGIA, 2018, 38 : 51 - 52
  • [33] Efficacy of galcanezumab in patients who failed to respond to preventives previously: results from EVOLVE-1, EVOLVE-2 and REGAIN studies
    Zhang, Q.
    Ruff, D. D.
    Pearlman, E. M.
    Govindan, S.
    Aurora, S. K.
    EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 298 - 298
  • [34] Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2) (vol 20, 75, 2019)
    Silberstein, Stephen D.
    Stauffer, Virginia L.
    Day, Katie A.
    Lipsius, Sarah
    Wilson, Maria-Carmen
    JOURNAL OF HEADACHE AND PAIN, 2019, 20 (01):
  • [35] Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial
    Skljarevski, Vladimir
    Matharu, Manjit
    Millen, Brian A.
    Ossipov, Michael H.
    Kim, Byung-Kun
    Yang, Jyun Yan
    CEPHALALGIA, 2018, 38 (08) : 1442 - 1454
  • [36] Galcanezumab in chronic migraine The randomized, double-blind, placebo-controlled REGAIN study
    Detke, Holland C.
    Goadsby, Peter J.
    Wang, Shufang
    Friedman, Deborah I.
    Selzler, Katherine J.
    Aurora, Sheena K.
    NEUROLOGY, 2018, 91 (24) : E2211 - E2221
  • [37] Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study
    Bo Hu
    Gang Li
    Xiaohong Li
    Shan Wu
    Tingmin Yu
    Xiang Li
    Hongru Zhao
    Zhihua Jia
    Junpeng Zhuang
    Shengyuan Yu
    The Journal of Headache and Pain, 2022, 23
  • [38] Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study
    Hu, Bo
    Li, Gang
    Li, Xiaohong
    Wu, Shan
    Yu, Tingmin
    Li, Xiang
    Zhao, Hongru
    Jia, Zhihua
    Zhuang, Junpeng
    Yu, Shengyuan
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (01):
  • [39] 100% RESPONSE RATE TO GALCANEZUMAB IN PATIENTS WITH EPISODIC MIGRAINE: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES
    Nagy, A. J.
    Pearlman, E.
    Ruff, D.
    Day, K.
    Aurora, S. K.
    Rosen, N.
    CEPHALALGIA, 2018, 38 : 63 - 64
  • [40] 100% response rate to galcanezumab in patients with episodic migraine: randomized, double-blind, placebo-controlled studies
    Nagy, Abraham Jim
    Pearlman, Eric
    Ruff, Dustin
    Day, Kathleen
    Rosen, Noah
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
12345